NCT01693133已完成不适用
A Multicenter, Prospective, Randomized, Controlled, Comparative Parallel Study of Dehydrated Human Amnion/Chorion Membrane (dHACM) Wound Graft in the Management of Diabetic Foot Ulcers
适应症
干预措施
试验速览
- 阶段
- 不适用
- 状态
- 已完成
- 入组人数
- 132
- 试验地点
- 39
- 主要终点
- Percentage of subjects with complete closure of the study ulcer
研究概览
简要总结
The objective of this study is to evaluate the percentage of patients with complete diabetic foot ulcer (DFU) closure following up to 12 weeks of treatment with either dehydrated human amnion/chorion membrane (dHACM) plus standard of care (SOC) or SOC alone.
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Parallel
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Male or female age 18 or older.
- •The patient is willing and able to provide informed consent and participate in all procedures and follow up evaluations necessary to complete the study.
- •Patient's ulcer must be diabetic in origin with a size ranging from 1 to 25 cm
- •Debridement will be done prior to randomization, if clinically indicated.
- •Wounds should be diabetic foot ulcers located on the dorsal or plantar surface of the foot.
- •Patients with Type 1 or 2 diabetes (criteria for the diagnosis of diabetes mellitus per ADA).
- •Ulcer must be present for a minimum of 30 days before enrollment/randomization, with documented failure of prior treatment to heal the wound (≤25% wound area reduction after 14 consecutive days of therapy immediately prior to randomization when treated with standard protocol of care).
- •Affected leg has been offloaded (removable walker or total contact cast) for >14 consecutive days prior to randomization.
- •Serum Creatinine less than 3.0mg/dl (within last 6 months).
- •HbA1c less than 12% within previous 60 days.
- •Patient has adequate circulation to the affected extremity, as demonstrated by one of the following within the past 60 days:
- •Dorsum transcutaneous oxygen test (TcPO2) with results ≥30mmHg, OR
- •ABIs with results of ≥0.7 and ≤1.2, OR
- •Doppler arterial waveforms, which are triphasic or biphasic at the ankle of affected foot.
- •Females of childbearing potential must be willing to use acceptable methods of contraception (birth control pills, barriers, or abstinence).
排除标准
- •Patients presenting with an ulcer probing to bone (UT Grade IIIA-D). A positive probe-tobone will be confirmed when bone or joint can be felt with a sterile, ophthalmological probe.
- •Patients with multiple wounds on the same foot where other wounds are within 3 cm of the wound under care.
- •Patients considered not in reasonable metabolic control, confirmed by an HbA1c 12% or greater at any time within previous 60 days.
- •Known history of poor compliance with medical treatments.
- •Patients currently enrolled in this study. Concurrent enrollment in the study is prohibited.
- •Patients treated with investigational drug(s) or therapeutic device(s) within 30 days.
- •Patients currently receiving radiation therapy or chemotherapy.
- •Known or suspected local skin malignancy to the index diabetic ulcer.
- •Patients diagnosed with autoimmune connective tissue diseases.
- •Non-revascularizable surgical sites.
- •Active infection at index site or currently being treated with antibiotics
- •Any pathology that would limit the blood supply and compromise healing.
- •Patients that have received a biomedical or topical growth factor for their wound within the previous 30 days. Study ulcer has been previously treated with tissue engineered materials (e.g. Apligraf® or Dermagraft®) or other scaffold materials (e.g. Oasis, Matristem) within the last 30 days.
- •Patients who are known to be pregnant, plan to become pregnant, or are breast feeding.
- •Known allergy to Gentamicin sulfate or Streptomycin sulfate.
- •Active Charcot deformity or major structural abnormalities of the foot.
- •Wounds that are greater than one year in duration without intermittent closure.
研究组 & 干预措施
Control
Other
Standard of Care: Moist Wound Therapy and Offloading
干预措施: Standard of Care: Moist Wound Therapy and Offloading (Other)
EpiFix plus Standard of Care
Experimental
Weekly application of EpiFix (up to 12 week) and standard of care (moist wound therapy and offloading)
干预措施: EpiFix plus Standard of Care (Other)
结局指标
主要结局
Percentage of subjects with complete closure of the study ulcer
时间窗: Week 12
Assessed by the Investigator, during treatment (Visits 1 - 13).
次要结局
- Time to complete closure for both groups(Up to 12 Weeks)
- Incidence of ulcer recurrence(Up to Week 16)
- Rate of wound closure(Up to Week 12)
- Cost effectiveness of treatment(Up to Week 12)
- Quality of Life(Up to Week 12)
研究者
研究点 (39)
Loading locations...
相似试验
终止
不适用
Blue Light Photobiomodulation Therapy on Neuroischemic PatientsDiabetic Foot UlcerNCT04831606Emoled21
撤回
1 期
Study of Safety, Tolerability, and Pharmacokinetics of Topical Selinexor (KPT-330) Diabetic Foot Ulcer (DFU) PatientsDiabetic Foot UlcersNCT02367690Karyopharm Therapeutics Inc
已完成
不适用
Effect of PATient Education Related to CV Risk factOrs in Type 2 Diabetes Mellitus(Patrol).GlycemiaHypertensionHyperlipidemiaNCT00891124AstraZeneca4,045
已完成
2 期
A Study to Investigate the Safety and Clinical Effect of Nexagon® as a Topical Treatment for Subjects With a Diabetic Foot Ulcer (DUNE)Diabetic Foot UlcersNCT01490879OcuNexus Therapeutics, Inc.168
尚未招募
不适用
Evaluating the Effect of Adipose Tissue Processed With the SyntrFuge™ System in the Healing of Diabetic Foot UlcersDiabetic Foot UlcerNCT05519501Syntr Health Technologies, Inc.62